Approved and Emerging Regimens for Frontline and Second Line Lower-Risk MDS

Guillermo Garcia-Manero, MD, highlights data updates presented at ASH 2023, outlining current and emerging therapies in frontline and second line lower-risk myelodysplastic syndrome (MDS).

EP: 1.Lower-Risk MDS: Current Treatment Landscape and Unmet Needs

Now Viewing

EP: 2.Approved and Emerging Regimens for Frontline and Second Line Lower-Risk MDS

EP: 3.Toxicity Management for Therapies in Lower-Risk MDS

EP: 4.New Horizons in the Management of MDS

Related Videos